Cancer Early Detection Market Targeted: Healthcare Giant Completes Mega Acquisition

On March 23 U.S. time, Abbott Laboratories (NYSE: ABT) completed its roughly $21 billion acquisition of Exact Sciences, making the company a wholly owned subsidiary and substantially strengthening Abbott’s position in the U.S. early-cancer screening and precision-oncology markets. The deal brings diagnostic assets such as Cologuard, Oncotype DX, OncoDetect and CancerGuard into Abbott’s portfolio. While Abbott expects the acquisition to accelerate global rollout of early-cancer tests and personalized-treatment tools, it also acknowledged integration risks and uncertainty around achieving full synergies.

To finance the deal, Abbott issued $20 billion of senior unsecured notes in eight tranches under its existing indenture pursuant to a late-February pricing agreement. Outside counsel issued a legal opinion confirming that, aside from customary bankruptcy-related exceptions, these notes constitute valid and binding obligations of the company. Meanwhile, Executive Vice President Jacob A. Oville was granted approximately 13,000 restricted common shares vesting over two years, increasing his direct equity stake to about $5.3 million (roughly ₩7 billion).

Separately, the U.S. Food and Drug Administration announced a Class I recall—the agency’s highest risk category—for Abbott’s FreeStyle Libre 3 and Libre 3 Plus continuous glucose monitors, citing a defect that can display blood-glucose readings lower than actual levels. The FDA noted seven deaths and hundreds of serious injuries reported worldwide in connection with the devices. In Chicago, a trial is underway over allegations that Abbott’s infant-formula products caused necrotizing enterocolitis in premature infants, marking yet another legal challenge for the company.

Headquartered in Abbott Park, Illinois, Abbott is a global healthcare leader supplying products in over 160 countries through its four business segments: Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals. Built on the commercial success of its FreeStyle Libre continuous-glucose-monitoring system, structural heart-disease devices, nutritional products and branded generics, Abbott has delivered steady growth—and with the addition of Exact Sciences, it now extends its reach into the fast-growing cancer-diagnostics and precision-oncology arena.